Lakefront Biotherapeutics | GLPG - Net Income


Lakefront Biotherapeutics reported EUR2.11M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
argenx SE USD 506M 34M Sep/2026
AstraZeneca USD 3.12B 610M Sep/2026
Biogen USD 97.5M 222M Jun/2026
Genmab DKK 303M 250M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
GRIFOLS EUR 162M 8M Sep/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Incyte USD -784.8M 1.37B Sep/2026
Merck EUR 490M 169M Jun/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Novartis USD 1.2B 2.06B Sep/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 3.02B 2.68B Sep/2026
UCB EUR 1.08B 608M Dec/2025
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026